In: Accounting
Calculate EV/EBITDA, PE ratio and dividend yield for CVS (CVS), WAG (Walgreens) and FRED (Fred’s). Also calculate year-over-year sales growth and EBITDA growth. Using these together with other information of your choosing, explain why you would or wouldn’t invest in each of them.
CVS
Income Statement
All numbers in thousands
Revenue | 12/31/2017 | 12/31/2016 | 12/31/2015 |
Total Revenue | 184,765,000 | 177,526,000 | 153,290,000 |
Cost of Revenue | 156,220,000 | 148,669,000 | 126,762,000 |
Gross Profit | 28,545,000 | 28,857,000 | 26,528,000 |
Operating Expenses | |||
Research Development | - | - | - |
Selling General and Administrative | - | - | - |
Non Recurring | - | - | - |
Others | - | - | - |
Total Operating Expenses | - | - | - |
Operating Income or Loss | 9,517,000 | 10,366,000 | 9,475,000 |
Income from Continuing Operations | |||
Total Other Income/Expenses Net | -208,000 | -671,000 | -21,000 |
Earnings Before Interest and Taxes | 9,309,000 | 9,695,000 | 9,454,000 |
Interest Expense | 1,041,000 | 1,058,000 | 838,000 |
Income Before Tax | 8,268,000 | 8,637,000 | 8,616,000 |
Income Tax Expense | 1,637,000 | 3,317,000 | 3,386,000 |
Minority Interest | 4,000 | 4,000 | 7,000 |
Net Income From Continuing Ops | 6,631,000 | 5,320,000 | 5,230,000 |
Non-recurring Events | |||
Discontinued Operations | -8,000 | -1,000 | 9,000 |
Extraordinary Items | - | - | - |
Effect Of Accounting Changes | - | - | - |
Other Items | - | - | - |
Net Income | |||
Net Income | 6,622,000 | 5,317,000 | 5,237,000 |
Preferred Stock And Other Adjustments | - | - | - |
Net Income Applicable To Common Shares | 6,622,000 | 5,317,000 | 5,237,000 |
WAG
Income Statement
All numbers in thousands
Revenue | 8/31/2017 | 8/31/2016 | 8/31/2015 |
Total Revenue | 118,214,000 | 117,351,000 | 103,444,000 |
Cost of Revenue | 89,052,000 | 87,477,000 | 76,691,000 |
Gross Profit | 29,162,000 | 29,874,000 | 26,753,000 |
Operating Expenses | |||
Research Development | - | - | - |
Selling General and Administrative | 23,605,000 | 23,873,000 | 22,085,000 |
Non Recurring | - | - | - |
Others | - | - | - |
Total Operating Expenses | - | - | - |
Operating Income or Loss | 5,557,000 | 6,001,000 | 4,668,000 |
Income from Continuing Operations | |||
Total Other Income/Expenses Net | -11,000 | -261,000 | 1,248,000 |
Earnings Before Interest and Taxes | 5,546,000 | 5,740,000 | 5,916,000 |
Interest Expense | 693,000 | 596,000 | 605,000 |
Income Before Tax | 4,853,000 | 5,144,000 | 5,311,000 |
Income Tax Expense | 752,000 | 953,000 | 1,032,000 |
Minority Interest | 808,000 | 401,000 | 439,000 |
Net Income From Continuing Ops | 4,078,000 | 4,173,000 | 4,220,000 |
Non-recurring Events | |||
Discontinued Operations | - | - | - |
Extraordinary Items | - | - | - |
Effect Of Accounting Changes | - | - | - |
Other Items | - | - | - |
Net Income | |||
Net Income | 4,078,000 | 4,173,000 | 4,220,000 |
Preferred Stock And Other Adjustments | - | - | - |
Net Income Applicable To Common Shares | 4,078,000 | 4,173,000 | 4,220,000 |
Fred's
Income Statement
All numbers in thousands
Revenue | 1/28/2017 | 1/31/2016 | 1/31/2015 |
Total Revenue | 2,125,424 | 2,150,703 | 1,970,049 |
Cost of Revenue | 1,615,162 | 1,606,553 | 1,466,256 |
Gross Profit | 510,262 | 544,150 | 503,793 |
Operating Expenses | |||
Research Development | - | - | - |
Selling General and Administrative | 537,931 | 508,897 | 511,142 |
Non Recurring | - | - | - |
Others | 47,027 | 45,652 | 41,063 |
Total Operating Expenses | - | - | - |
Operating Income or Loss | -74,696 | -10,399 | -48,412 |
Income from Continuing Operations | |||
Total Other Income/Expenses Net | - | - | - |
Earnings Before Interest and Taxes | -74,696 | -10,399 | -48,412 |
Interest Expense | 2,318 | 1,431 | 504 |
Income Before Tax | -77,014 | -11,830 | -48,916 |
Income Tax Expense | -10,483 | -4,459 | -20,012 |
Minority Interest | - | - | - |
Net Income From Continuing Ops | -66,531 | -7,371 | -28,904 |
Non-recurring Events | |||
Discontinued Operations | - | - | - |
Extraordinary Items | - | - | - |
Effect Of Accounting Changes | - | - | - |
Other Items | - | - | - |
Net Income | |||
Net Income | -66,531 | -7,371 | -28,904 |
Preferred Stock And Other Adjustments | - | - | - |
Net Income Applicable To Common Shares | -66,531 | -7,371 | -28,904 |
In the absence of Balance Sheet data, it is not possible to calculate Enterprise Value (EV). Therefore to calculate EV/EBITDA is not possible.
Based on the Income statement data, one will not invest in Fred at all since the EBITDA is negative. However among the other 2, one should invest in CVS because of higher EBITDA margins and better growth. 2017 seems to be a disturbed year for everyone so one has to avoid such non-recurring phase and accordingly base their decisions.